BG62554B1 - Метод за получаване на силденафил - Google Patents

Метод за получаване на силденафил Download PDF

Info

Publication number
BG62554B1
BG62554B1 BG101569A BG10156997A BG62554B1 BG 62554 B1 BG62554 B1 BG 62554B1 BG 101569 A BG101569 A BG 101569A BG 10156997 A BG10156997 A BG 10156997A BG 62554 B1 BG62554 B1 BG 62554B1
Authority
BG
Bulgaria
Prior art keywords
solvent
acid
cycloalkyl
alkyl
alkanol
Prior art date
Application number
BG101569A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG101569A (en
Inventor
Peter J. Dunn
Albert S. Wood
Original Assignee
Pfizer Research аnd Development Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG62554(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Research аnd Development Company filed Critical Pfizer Research аnd Development Company
Publication of BG101569A publication Critical patent/BG101569A/xx
Publication of BG62554B1 publication Critical patent/BG62554B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BG101569A 1996-06-14 1997-06-05 Метод за получаване на силденафил BG62554B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9612514.1A GB9612514D0 (en) 1996-06-14 1996-06-14 Novel process

Publications (2)

Publication Number Publication Date
BG101569A BG101569A (en) 1998-01-30
BG62554B1 true BG62554B1 (bg) 2000-02-29

Family

ID=10795332

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101569A BG62554B1 (bg) 1996-06-14 1997-06-05 Метод за получаване на силденафил

Country Status (48)

Country Link
US (2) US5955611A (sk)
EP (2) EP0812845B1 (sk)
JP (2) JP2866841B2 (sk)
KR (1) KR100207352B1 (sk)
CN (2) CN1106399C (sk)
AP (1) AP717A (sk)
AR (1) AR003401A1 (sk)
AT (2) ATE246194T1 (sk)
AU (1) AU697684B2 (sk)
BG (1) BG62554B1 (sk)
BR (1) BR9703580A (sk)
CA (1) CA2207694C (sk)
CO (1) CO4780028A1 (sk)
CZ (1) CZ290942B6 (sk)
DE (2) DE69700321T2 (sk)
DK (2) DK0916675T3 (sk)
DZ (1) DZ2247A1 (sk)
EA (1) EA000102B1 (sk)
EG (1) EG24123A (sk)
ES (2) ES2201397T3 (sk)
GB (1) GB9612514D0 (sk)
GR (1) GR3031087T3 (sk)
HK (1) HK1033459A1 (sk)
HN (1) HN1997000072A (sk)
HR (1) HRP970326B1 (sk)
HU (1) HU224497B1 (sk)
ID (1) ID18745A (sk)
IL (3) IL121000A (sk)
IN (5) IN187350B (sk)
IS (2) IS1922B (sk)
MA (1) MA24205A1 (sk)
MX (1) MX9704433A (sk)
NO (2) NO304551B1 (sk)
NZ (1) NZ328084A (sk)
OA (1) OA10426A (sk)
PE (2) PE20011303A1 (sk)
PL (1) PL189333B1 (sk)
PT (1) PT916675E (sk)
RS (2) RS49924B (sk)
SA (1) SA97180124B1 (sk)
SG (1) SG50024A1 (sk)
SI (2) SI0916675T1 (sk)
SK (5) SK283896B6 (sk)
TN (1) TNSN97102A1 (sk)
TR (1) TR199700470A2 (sk)
UA (1) UA27085C2 (sk)
UY (2) UY24585A1 (sk)
ZA (1) ZA975259B (sk)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
CZ299633B6 (cs) * 1997-04-25 2008-09-24 Pfizer Inc. Pyrazolopyrimidinony, meziprodukty pro jejich výrobu a farmaceutické a veterinární kompozice na jejich bázi
BR9809508A (pt) * 1997-05-29 2000-06-20 Mochida Pharm Co Ltd Agente terapêutico para disfunção de ereção
US6399618B1 (en) 1997-07-09 2002-06-04 Cardiome Pharma Corp Compositions and methods for modulating sexual activity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
EP2295436A1 (de) 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren
HUP0102543A3 (en) * 1998-04-20 2002-01-28 Pfizer Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them
CA2235642C (en) 1998-05-15 2007-11-13 Torcan Chemical Ltd. Processes for preparing sildenafil
DE69916627T2 (de) * 1998-09-04 2005-07-28 Ortho-Mcneil Pharmaceutical, Inc. 5-heterozyklyl-pyrazolo[4,3-d]pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen
GB9822238D0 (en) * 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
AU5204800A (en) * 1999-06-21 2001-01-09 Biochemical Pharmaceutical Factory of Zhuhai Sez, The Process for preparing sildenafil, and troche which comprises sildenafil and apomorphine
CN1094492C (zh) * 1999-06-21 2002-11-20 杭州神鹰医药化工有限公司 西地那非的制备方法
CN1077108C (zh) * 1999-07-13 2002-01-02 成都地奥制药集团有限公司 用于制备药物昔多芬的前体化合物
WO2001019827A1 (en) * 1999-09-13 2001-03-22 Cipla Ltd. A novel process for the synthesis of sildenafil citrate
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
AP2002002455A0 (en) 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6667398B2 (en) 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
US6730786B2 (en) 2000-06-22 2004-05-04 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
GB0015462D0 (en) * 2000-06-22 2000-08-16 Pfizer Ltd Novel process for the preparation of pyrazolopyrimidinones
EP1296983B1 (en) * 2000-06-22 2004-11-17 Pfizer Limited Novel process for the preparation of pyrazolopyrimidinones
YU51701A (sh) * 2000-07-28 2003-12-31 Pfizer Inc. Postupak za dobijanje jedinjenja pirazola/4,3-d/ pirimidin-7-ona i njihovih derivata
EP1176142A1 (en) * 2000-07-28 2002-01-30 Pfizer Inc. Process for the preparation of pyrazoles
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
JP4450365B2 (ja) * 2001-08-28 2010-04-14 シェーリング コーポレイション 多環式グアニンホスホジエステラーゼｖ阻害剤
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
CN100360531C (zh) * 2003-12-18 2008-01-09 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防或治疗阳萎和性冷淡的新吡唑并嘧啶类化合物
EP1779852A3 (en) * 2004-01-05 2007-05-09 Teva Pharmaceutical Industries Ltd. Processes for the production of sildenafil base and citrate salt
ATE387203T1 (de) * 2004-01-05 2008-03-15 Teva Pharma Prozesse zur herstellung von sildenafil-base und zitratsalz
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
WO2008074194A1 (fr) * 2006-12-21 2008-06-26 Topharman Shanghai Co., Ltd. Procédé de préparation du sildénafil et de ses intermédiaires
ES2310144B1 (es) 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
MX339136B (es) 2008-12-12 2016-05-13 Rhein Siegfried Sa De Cv Composicion de liberacion pulsatil de sildenafil y proceso para prepararla.
MX2010006227A (es) 2010-06-07 2011-12-14 World Trade Imp Exp Wtie Ag Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
CN102993205B (zh) * 2012-12-27 2015-04-15 华润赛科药业有限责任公司 一种高收率制备高纯度西地那非游离碱的纯化方法
CN103044330B (zh) * 2013-01-14 2018-11-13 常州亚邦制药有限公司 西地那非中间体4-氨基-1-甲基-3-正丙基吡唑-5-甲酰胺的绿色合成新工艺
CN105085526B (zh) * 2014-05-15 2017-08-01 重庆圣华曦药业股份有限公司 一种改进的西地那非制备方法
CN105753870B (zh) * 2016-04-01 2018-05-22 重庆康刻尔制药有限公司 一种西地那非杂质f及其制备方法和应用
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN105837578A (zh) * 2016-04-05 2016-08-10 重庆康刻尔制药有限公司 一种西地那非杂质d的合成方法
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用
CN112961160A (zh) * 2021-03-05 2021-06-15 遂成药业股份有限公司 一种西地那非的改良合成工艺
CN113754612B (zh) * 2021-10-26 2023-09-26 山东安舜制药有限公司 一种西地那非中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871843A (en) * 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
CZ299633B6 (cs) * 1997-04-25 2008-09-24 Pfizer Inc. Pyrazolopyrimidinony, meziprodukty pro jejich výrobu a farmaceutické a veterinární kompozice na jejich bázi
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
SK283894B6 (sk) 2004-04-06
UY24585A1 (es) 1997-12-02
IN187317B (sk) 2002-03-23
IN187350B (sk) 2002-03-30
EG24123A (en) 2008-07-06
EA000102B1 (ru) 1998-08-27
NO304551B1 (no) 1999-01-11
JP2866841B2 (ja) 1999-03-08
SK283896B6 (sk) 2004-04-06
NO972481L (no) 1997-12-15
AR003401A1 (es) 1998-08-05
CA2207694A1 (en) 1997-12-14
US6066735A (en) 2000-05-23
NO306115B1 (no) 1999-09-20
TR199700470A2 (xx) 1998-01-21
ID18745A (id) 1998-05-07
NZ328084A (en) 1998-08-26
SA97180124A (ar) 2005-12-03
HN1997000072A (es) 1997-12-26
IS1922B (is) 2004-03-15
AU697684B2 (en) 1998-10-15
IN187319B (sk) 2002-03-23
IL121000A0 (en) 1997-11-20
OA10426A (en) 2001-12-07
SG50024A1 (en) 1998-06-15
IL125411A (en) 2000-02-29
ATE182150T1 (de) 1999-07-15
SK74397A3 (en) 1998-06-03
CO4780028A1 (es) 1999-05-26
KR980002051A (ko) 1998-03-30
EP0812845B1 (en) 1999-07-14
EP0916675B1 (en) 2003-07-30
GR3031087T3 (en) 1999-12-31
CZ290942B6 (cs) 2002-11-13
NO972481D0 (no) 1997-05-30
IS6634A (is) 2002-11-25
DE69723846D1 (de) 2003-09-04
HU224497B1 (hu) 2005-10-28
RS49653B (sr) 2007-09-21
HU9701048D0 (en) 1997-08-28
IS1923B (is) 2004-03-15
US5955611A (en) 1999-09-21
NO985064D0 (no) 1998-10-30
ZA975259B (en) 1997-12-15
AP717A (en) 1999-01-04
ES2134051T3 (es) 1999-09-16
GB9612514D0 (en) 1996-08-14
KR100207352B1 (en) 1999-07-15
ATE246194T1 (de) 2003-08-15
DE69700321T2 (de) 1999-11-04
JPH1081688A (ja) 1998-03-31
SI0812845T1 (en) 1999-12-31
DE69723846T2 (de) 2004-03-04
MA24205A1 (fr) 1997-12-31
SK283893B6 (sk) 2004-04-06
HUP9701048A3 (en) 2000-10-30
UA27085C2 (uk) 2000-02-28
PE20011303A1 (es) 2001-12-25
HRP970326B1 (en) 2000-10-31
CN1106399C (zh) 2003-04-23
RS20060484A (en) 2007-04-10
MX9704433A (es) 1998-11-30
HRP970326A2 (en) 1998-06-30
PE1299A1 (es) 1999-01-13
SK283897B6 (sk) 2004-04-06
AU2487897A (en) 1997-12-18
HUP9701048A2 (hu) 1998-12-28
IL125411A0 (en) 1999-03-12
JPH11171879A (ja) 1999-06-29
EP0812845A1 (en) 1997-12-17
PL189333B1 (pl) 2005-07-29
NO985064L (no) 1997-12-15
BR9703580A (pt) 1998-11-10
BG101569A (en) 1998-01-30
PL320555A1 (en) 1997-12-22
EP0916675A3 (en) 1999-07-14
PT916675E (pt) 2003-11-28
IN187320B (sk) 2002-03-23
DE69700321D1 (de) 1999-08-19
CN1168376A (zh) 1997-12-24
SA97180124B1 (ar) 2006-02-08
SK283895B6 (sk) 2004-04-06
DZ2247A1 (fr) 2002-12-18
SI0916675T1 (en) 2003-12-31
ES2201397T3 (es) 2004-03-16
AP9701009A0 (en) 1997-07-31
CN1282740A (zh) 2001-02-07
DK0916675T3 (da) 2003-10-27
CN1149206C (zh) 2004-05-12
JP3058863B2 (ja) 2000-07-04
CA2207694C (en) 1999-11-23
HK1033459A1 (en) 2001-08-31
EP0916675A2 (en) 1999-05-19
IN187318B (sk) 2002-03-23
IL121000A (en) 2000-02-29
YU25497A (sh) 1998-12-23
UY24612A1 (es) 2000-09-29
RS49924B (sr) 2008-09-29
DK0812845T3 (da) 1999-11-29
IS4503A (is) 1997-12-15
EA199700061A1 (ru) 1997-12-30
TNSN97102A1 (fr) 2005-03-15
CZ181197A3 (cs) 1998-03-18

Similar Documents

Publication Publication Date Title
BG62554B1 (bg) Метод за получаване на силденафил
KR20000028987A (ko) 피라졸로[4,3-디]피리미딘-7-온 및 그의 중간체의 제조방법
EP1375487B1 (en) Process for producing quinoline-3-carboxylic acid compounds
EP0897924B1 (en) Process for the preparation of tetrahydro-indolizines
JP3629052B2 (ja) 置換キナゾリン− ２，４− ジオンの製造方法
KR20020052213A (ko) 6-메틸-2-(4-메틸-페닐)-이미다조[1,2-ａ]피리미딘-3-(Ｎ,Ｎ-디메틸-아세트아미드) 및 중간체의 제조 방법
US4292431A (en) Process for the production of hydroxymethylimidazoles
AU647562B2 (en) Process and intermediate for certain bis-aza-bicyclic anxiolytic agents
EP0916656B1 (en) A method for production of pyrrolidinone derivatives
US5175300A (en) Process for preparing pyridine-2,3-dicarboxylic acid compounds
JP3851368B2 (ja) 置換キナゾリン− ２，４− ジオンの製法
KR100364226B1 (ko) 7-할로-1-시클로프로필-6-플루오로-4-옥소-1,4-디히드로-[1.8]나프티리딘-3-카복실레이트의 제조방법
EP0357792A1 (en) Process for preparing pyridine-2,3-dicarboxylic acid compounds
JPS63112580A (ja) テトラヒドロピリド〔２，３−ｄ〕ピリミジン誘導体
JPS6212785B2 (sk)
JPH06298728A (ja) ピロール誘導体の製造法
JPS63145285A (ja) ５−（２−クロロベンジル）−４，５，６，７−テトラヒドロチエノ〔３，２−ｃ〕ピリジン又はその塩の製造方法